Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888819477Aexternal-prioritypatent/GB8819477D0/en
Priority claimed from GB888819480Aexternal-prioritypatent/GB8819480D0/en
Priority claimed from GB888819478Aexternal-prioritypatent/GB8819478D0/en
Application filed by The Wellcome Foundation LtdfiledCriticalThe Wellcome Foundation Ltd
Publication of MY105807ApublicationCriticalpatent/MY105807A/en
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
THE PRESENT INVENTION RELATES TO THE USE OF KNOWN AND NOVEL NAPHTHOQUINONES IN THE TREATMENT AND PROPHYLAXIS OF PNEUMOCYSTIS CARINII INFECTIONS, AND FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT AND PROPHYLAXIS OF P.CARINII INFECTIONS, NOVEL FORMULATIONS CONTAINING SAID COMPOUNDS, AND NOVEL NAPHTHOQUINONES OF FORMULA (V1): WHEREIN R11 AND R12 EACH REPRESENT=O AND THE DOTTED LINE REPRESENTS A DOUBLE BOND BETWEEN THE 2 AND 3 POSITIONS OF THE QUINONE RING, IN WHICH CASE R13 REPRESENTS A GROUP -OCOR5; A GROUP OR6 OR SR6; OR A GROUP NR7R8; OR THE DOTTED LINE REPRESENTS DOUBLE BONDS AT THE 1,2 AND 3,4 POSITIONS OF THE QUINOL RING AND R11, R12 AND R13 EACH REPRESENTS A GROUP -OCOR14, WHEREIN R14 REPRESENTS AN OPTIONALLY SUBTITUTED C1-10 ALKYL GROUP.
Medicament containing a pharmaceutically acceptable carrier and the compound of the structure (7-alpha, 17-alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -ene-20-yne-3 -one contains.